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ABSTRACT
Background. The relative eYcacy and safety of lacosamide as adjunctive therapy
comparedtootherantiepilepticdrugshasnotbeenwellestablished.
Objective. To determine if lacosamide provides improved eYcacy and safety, re-
duced length of hospital stay and improved quality of life compared with other
anti-epileptictherapiesforadultswithpartial-onsetseizures.
Data Sources. A systematic review of the medical literature using Medline
(1946–Week 4, 2012), EMBASE (1980–Week 3, 2012), Cochrane Central Register
of Controlled Trials (Issue 1 of 12, January 2012). Additional studies were identiﬁed
(through to February 7, 2012) by searching bibliographies, the FDA drug approval
ﬁles, clinical trial registries and major national and international neurology meeting
abstracts.Norestrictionsonpublicationstatusorlanguagewereapplied.
Study Selection. Randomized controlled trials of lacosamide in adults with partial-
onsetseizureswereincluded.
Data Extraction. Study selection, extraction and risk of bias assessment were per-
formedindependentlybytwoauthors.Authorsofstudieswerecontactedformissing
data.
Data Synthesis.AllpooledanalysesusedtherandomeVectsmodel.
Results. Three trials (1311 patients) met inclusion criteria. Lacosamide increased
the 50% responder rate compared to placebo (RR 1.68 [95% CI 1.36 to 2.08];
I2 D 0%).Discontinuationduetoadverseeventswasstatisticallysigniﬁcantlyhigher
in the lacosamide arm (RR3.13 [95% CI 1.94 to 5.06]; I2 D 0%). Individual adverse
events (ataxia, dizziness, fatigue, and nausea) were also signiﬁcantly higher in the
lacosamidegroup.
Limitations.Alldosagearmsfromtheincludedstudieswerepooledtomakeasingle
pair-wisecomparisontoplacebo.Selectivereportingofoutcomeswasfoundinallof
theincludedRCTs.
Conclusions. Lacosamide as adjunctive therapy in patients with partial-onset
seizures increases the 50% responder rate but with signiﬁcantly more adverse events
comparedtotheplacebo.
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INTRODUCTION
EpilepsyaVects15,500newCanadiansannually(EpilepsyCanada,2011)withpartial-onset
seizuresbeingthemostcommonseizuretypeinadults-aVectingupto60%ofadultswho
have epilepsy (Epilepsy Canada, 2011). Up to one-third of newly-diagnosed patients are
refractory to drug therapy and this presents a therapeutic challenge (Beyenburg, Stavem &
Schmidt,2010).Adjunctivetherapywithantiepilepticdrugs(AEDs)isthestandardofcare
for patients with refractory epilepsy (French, Kanner & Bautista, 2004). However, current
guidelines (French, Kanner & Bautista, 2004) do not address the more recently-available
AEDs,includinglacosamide,forthetreatmentofrefractoryepilepsy.
LacosamideisanovelAED,consistingofafunctionalizedaminoacidmoleculebelieved
to stabilize hyperexcitable neuronal membranes and inhibit repetitive neuronal ﬁring
(Lexi-Drugs, 2011). Health Canada has approved lacosamide for use as adjunctive therapy
in the management of partial-onset seizures in adult patients with epilepsy who are not
satisfactorily controlled with conventional therapy (Canadian Pharmacists Association,
2011).
All previously-published systematic reviews of lacosamide (Beyenburg, Stavem &
Schmidt, 2010; Beydoun et al., 2009; Chung et al., 2010a; Simoens, 2011; Costa et al., 2011;
Ryvlin,Cucherat&Rheims,2011)haveconcludedthatlacosamideiseYcaciousinreducing
seizure frequency compared to placebo, but each review had methodological challenges
limiting its interpretability. To better estimate the eVect size of lacosamide, this systematic
reviewwasdesignedtoincludealldosesoflacosamidestudied,usingtheintentiontotreat
population, and considering all important outcomes, in addition to closely examining
lacosamide’s adverse events (which have not been adequately explored in the previous
reviews).
The objective of this systematic review was to determine the relative beneﬁts and harm
oflacosamidetherapycomparedtootherAEDsorplacebo,asadjunctivetherapyforadults
withpartial-onsetseizures.
METHODS
Protocol and registration
The search strategy, methods of analysis and inclusion criteria were speciﬁed in advance
anddocumentedinaprotocol.Theprotocolforthissystematicreviewwasregisteredwith
the Prospective International Register of Systematic Reviews (PROSPERO) and can be
foundonline(Sawh&Newman,2012).
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Studies were identiﬁed by searching the following electronic databases: Medline (OVID
1946toWeek4,2012),EMBASE(OVID,1980toWeek32012),CochraneCentralRegister
ofControlledTrials(CENTRAL)(WileyIssue1of12,January2012).
We contacted the manufacturer of lacosamide and experts in the ﬁeld for information
about unpublished or ongoing studies. The Food and Drug Administration’s (FDA)
Approved Drug Products database was searched for clinical trials used to support
marketing approval and/or labelling changes in the United States. Conference abstracts
andpostersweresearchedfromselectedmeetingsoftheAmericanEpilepsySociety,World
Congress of Neurology, International Epilepsy Congress, and the European Congress on
Epileptology. We also searched the metaRegister of Controlled Trials (mRCT) to identify
ongoingtrials.
Referencelistsofallretrievedstudieswerereviewedforadditionalrelevantstudies.
The search was developed and conducted by one of the authors (SS) and reviewed by a
Research Librarian (KC). The last search was run February 7, 2012. We used the following
search terms to search all trial registers and databases (modiﬁed to suit each speciﬁc
database): randomized controlled trials, epilepsy, seizures, partial epilepsy, lacosamide,
and Vimpat. No language restrictions were imposed on the electronic database searches.
Theonlineprotocolprovidesthedetailedsearchstrategyusedinthisreview.
Study selection
Title and abstract screening was conducted in duplicate to identify potentially eligible
papers using a standardized guide for trial inclusion based on title and abstract screening.
Two reviewers (JN and SS) underwent a calibration process to identify potential
discrepancies in interpretation of the form (with the ﬁrst 100 citations as a sample).
Publications that could possibly have met the selection criteria were retrieved as full-text
articlesandexamined.
Full-text screening was conducted, independently by two reviewers, to conﬁrm
eligibility using a standardized screening form (Table S1). We used Fleiss and Cohen’s
weighted Kappa (using the program Kappa.exe (Cyr & Francis, 1992)) to assess agreement
between the two reviewers on the selection of full-text articles for inclusion (Fleiss &
Cohen,1973).Alldisagreementswereresolvedbydiscussion.
We documented the study selection process in a ﬂow chart as recommended in the
PRISMAstatement(Liberatietal.,2009)showingthetotalnumbersofretrievedreferences
andthenumbersofincludedandexcludedstudies,andthereasonsforexclusion(Fig.1).
Data collection process & data items
Data were extracted independently by two reviewers (JN and SS) using an a priori
standardized data extraction form with the aid of a data and validity extraction manual.
The two sets of extracted data were compared and all discrepancies were resolved by
discussion. Data was extracted from each included trial on the following general areas
ofinformation:
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 Numberofparticipatingcentresandcountries
 Inclusioncriteria
 Exclusioncriteria
 Numberofpatientseligibleandrandomized
 Treatmentdurationandlengthoffollow-upofpatientoutcomes
 Datacollectiontimepoints
 Treatmentarmsinthetrials
 Ethicsreviewboardapprovalandpatientconsenttoparticipate
 Fundingsource
Participant characteristics
 Numberofpatientsrandomizedandwithavailableoutcomedata
 Epilepsydiagnosis
 AEDuse(numberandtypes)
Primary and secondary outcomes
 Outcomedeﬁnition
 Directionofoutcome(i.e.,harmorbeneﬁt)
 Timepoint(s)ofoutcomeevaluation
 Outcome unit of measurement and measure of error (if continuous). Where possible,
for continuous measures, mean outcome values and standard deviations were recorded
ordeterminedasmeasurementsofoutcome.
Study authors were contacted by e-mail to request information about missing data
for included trials. For studies with multiple publications, all versions of the study were
reviewed to ensure complete access to maximal trial data. In the event of inconsistency
of study data between multiple publications (for example, between a Food and Drug
Administration submission and a peer-reviewed paper published in a journal), the
peer-reviewedpublicationwasusedastheprimarydataset.
Risk of bias in individual studies
Two reviewers (JN and SS) independently assessed the risk of bias for each included
study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins, Altman & Sterne, 2011). Reviewers were not blinded to the study
authors, journal or outcome data. We speciﬁcally assessed the trial characteristics as
speciﬁedintheprotocol.
 sequencegeneration;
 allocationconcealment;
 blinding of the study (participants, personnel, outcome assessors, data collectors, data
analysts)asdeﬁnedbyAkletal.(2012);
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 selectiveoutcomereporting;
 othersourcesofbias.
A summary table and a graph for risk of bias were created using Review Manager
software5.1(TheNordicCochraneCentre,2011).
Synthesis of results
We calculated the pooled relative risks (RRs) and 95% conﬁdence intervals (CI) for
dichotomous variables using the Mantel-Haenszel method (Deeks, Higgins & Altman,
2011). For continuous variables measured using the same scales, the mean diVerences
(MD) and its 95% CI were calculated using the inverse variance method. If a continuous
outcome variable was measured using diVerent scales across studies, we calculated the
standardizedmeandiVerence(SMD).
All of our analyses included the total numbers of participants in the treatment groups
to which they had been allocated (intention to treat analysis). Participants not completing
followuporwithinadequateseizuredatawereassumedtobenon-responders.
We contacted study authors for clariﬁcation if more information was needed, and to
requestmissingdata.
Randomized trials included multiple dosages of lacosamide in separate randomized
arms.Forthepurposeofthemeta-analysis,alllacosamidedosageswerecombinedintoone
“lacosamide”arm(CochraneHandbookforSystematicReviewsofInterventions,2011).
We tested statistically for heterogeneity with a chi-square test and used I2 to measure
inconsistency (the percentage of total variation across studies due to heterogeneity).
We used “small,” (25%), “moderate” (between 25% and 50%) and “large” (50%) to
describe the statistical heterogeneity as measured by I2 (Higgins et al., 2003). Forest plots
werevisuallyinspectedforpossiblesourcesofheterogeneity.
A summary of ﬁndings table was created using GRADEpro software for the three
primary outcomes of this review (Brozek, Oxman & Sch¨ unemann, 2008). We planned to
assessthepossibilityofpublicationbiasbyusingfunnelplots(Egger&DaveySmith,1995).
Additional analyses
The following subgroup analyses were pre-speciﬁed for primary outcomes: patients
younger than 18 years old (if the pediatric outcome data was reported as a discrete
subgroup), placebo vs. active comparators, intravenous vs. oral lacosamide, and com-
paring studies with high vs. low risk of bias. Post-hoc, the potential of a dose-response
relationship of lacosamide was explored using subgroup analysis to look at the various
dosagelevelsstudiedforallthreeprimaryoutcomes.
The a priori sensitivity analyses for the primary outcomes were: (1) Best case -
Participants not completing follow-up or with inadequate seizure data were assumed to
be responders in the lacosamide group and non-responders in the control group. For the
primary safety outcome, participants not completing follow-up or with inadequate data
were assumed to have continued in the trial in the lacosamide arms and discontinued
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 6/26if in the control arm. (2) Worst case - Participants not completing follow-up or with
inadequate seizure data were assumed to be non-responders in the lacosamide group
and responders in the control group. For the primary safety outcome, participants not
completing follow-up or with inadequate data were assumed to have discontinued due to
adverse events in their respective lacosamide groups and to have stayed in if in the control
group.
RESULTS
Study selection
A total of 11 reports involving 3 studies were identiﬁed for inclusion in the review. The
search of Medline, EMBASE, and CENTRAL provided a total of 200 citations. The search
for unpublished literature (expert survey, manufacturer request, clinical trial registries,
and conference abstract proceedings) provided a total of 207 citations. After removing
duplicates, 357 citations independently underwent abstract review and 77 citations were
considered potentially relevant studies. Of the 77 full-text articles screened, 66 citations
were excluded. Three randomized controlled trials (Ben-Menachem et al., 2007; Chung
et al., 2010b; Hal´ asz et al., 2009) (located as 11 publications (Massie, 2007; Kalviainen et
al., 2007; Hal´ asz et al., 2006; Chung et al., 2007a; Chung et al., 2009b; Jatuzis et al., 2005;
Ben-Menachem et al., 2005; Chung et al., 2007b), that studied 1311 participants, met the
inclusion criteria for this review. The weighted kappa statistic for inter-rater agreement
on including or excluding potential trials was “excellent” [k D 0:90, 95% CI (0.83, 0.97)]
(Fleiss&Cohen,1973).SeeﬂowdiagramFig.1.
Study characteristics
See Table 1 for the characteristics of the included studies and Table S2 for the table of
excludedstudies.
Methods
Allthreestudiesselectedforthereviewwererandomized,controlled,parallelgroupstudies
publishedinEnglish.Thedurationoftheinterventionwas18weeksfortheBen-Menachem
et al. (2007) and Chung et al. (2010b) trials and 16 weeks for the Hal´ asz et al. (2009) trial.
Alltrialshadan8-weekmonitoringperiodbeforebaselineanda2-weektaperortransition
to oV or open-label continuation of lacosamide at the end of the maintenance phases. The
maintenance phase extension trials (Husain et al., 2011; Rosenfeld et al., 2011b; Rosenow
et al., 2011) did not meet the criteria for inclusion in this review and are not considered
further.
Participants
The included studies involved 1311 randomized participants from Australia, Europe,
and the USA. Three participants in the Ben-Menachem trial (Ben-Menachem et al.,
2007) were removed from the study after randomization for protocol violations and it
could not be determined which dosage arm they belonged to. Patients were included in
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Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 9/26these studies if they had a diagnosis of partial-onset seizures (with or without secondary
generalizations) that was objectively conﬁrmed (with electroencephalogram (EEG) and
magnetic resonance imaging (MR) or computed tomography (CT) scan). In order to be
eligible, patients must have had partial-onset seizures for at least the previous two years
despite treatment with at least two AEDs. For all three trials, to be counted as having
“current seizures”, participants must have had at least 4 partial-onset seizures per 28 days
on average with no seizure-free period longer than 21 days. For the Ben-Menachem trial,
the above inclusion criteria applied to the 8 week baseline period, whereas in the Chung et
al. (2010b) and Hal´ asz et al. (2009) trials, the seizure frequency criteria also applied to the
8 weeks prior to baseline. All patients needed to have stable AED regimens for the 4 weeks
priortoenrollmentandthebaselineperiod.IntheBen-Menachemtrial,regimenscouldbe
1or2AEDswithorwithoutvagalnervestimulation(VNS).IntheChungetalandHal´ asz
et al trials, patients’ regimens could consist of 1–3 AEDs with or without VNS. Participant
agewasrestrictedtoover16yearsintwotrials(Chungetal.,2007b;Hal´ aszetal.,2009)and
over 18 years in one trial (Ben-Menachem et al., 2007). Pediatric data was not presented
separatelyinthetwostudiesthatincludedpatientslessthan18yearsofage.
Intervention
All three studies compared adjunctive oral lacosamide in multiple doses to placebo
(no active comparators) in a minimum of three comparator arms. All three trials had
a lacosamide 200 mg twice daily arm. Ben-Menachem et al. and Hal´ asz et al. both
had lacosamide 100 mg twice daily arms. Chung et al and Ben-Menachem included a
lacosamide300mgtwicedailyarm.Nostudiesincludedintravenouslacosamide.
Outcomes
The primary outcomes for the three studies were change in seizure frequency (per 28 days
from baseline to the maintenance period) and 50% responder rate. All three publications
reported 50% responder rate in percentage, so the eYcacy analysis denominators
were used to convert to the number of patients who achieved the 50% response rate.
Discontinuation due to adverse events was reported in all studies, as were individual
adverse events. If percentages were provided for adverse event endpoints, they were
converted to numbers of patients experiencing an event using the denominators provide
for the safety analysis in the full publications. Quality of life outcomes were measured by
twoofthethreestudies(Ben-Menachemetal.,2007;Hal´ aszetal.,2009),butonlyreported
by Ben-Menachem et al. (2007). Timing of outcome measures varied with the end of the
maintenanceperiodasdeﬁnedbytheindividualstudies.
Risk of bias within studies
SeeFig.2.
All three studies were randomized-controlled trials, and all studies except Ben-
Menachempresentedthemethodofrandomsequencegeneration.Allocationconcealment
and blinding of participants, personnel, and outcome assessors were adequately reported
for all trials. Incomplete outcome data reporting was present for all three trials. Selective
outcome reporting was noted for all three included trials, as assessed by comparison of
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 10/26Figure2 Riskofbiassummary.
the published trials to the studies submitted for FDA approval. None of the three trials
did a formal ITT analysis, but used all patients who received at least one dose of study
medicationastheirdeﬁnitionofthestudypopulation.
Results of individual studies
Primary outcomes
The mean change in seizure frequency from maintenance phase to baseline was not
provided in any of the three included studies. The authors of each study were contacted in
anattempttoprocuretheseizurefrequencychangedata,butnoinformationwasprovided.
Theprimaryoutcomedataavailablefromthethreetrials(“percentreductioninseizure
frequency”)ispresentedinTable2.Therewasalargermedianpercentchange(asnotedby
thetrialauthors)withthehigherdosagearmsoflacosamidecomparedtoplacebo.
The 50% responder rate was reported for all three included trials and the results are
presented in Fig. 3. In the meta-analysis of this primary outcome (ITT), lacosamide
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 11/26Table2 Medianpercentagereductioninseizurefrequency.*
Trial Placebo Lacosamide
200mg/day
Lacosamide
400mg/day
Lacosamide
600mg/day
N % N % N % N %
Ben-Menachem et al. (2007) 96 10% 107 26% 107 39% 105 40%
Chung et al. (2010b) 104 20.8% – – 201 37.3% 97 37.8%
Hal´ asz et al. (2009) 159 20.5% 160 35.3% 158 36.4% – –
Notes.
* Compares maintenance phase to baseline period.
Figure3 50%responderrate(ITT). Primary outcome (ITT) lacosamide (all dosage arms pooled) compared to placebo.
(all dosage arms pooled) was associated with a signiﬁcantly higher 50% response rate
compared to placebo (RR 1.68, 95% CI 1.36, 2.08). There was no evidence of statistical
heterogeneity (I2 D 0%). The analyses of worst-case scenarios and best –case scenarios
bothproducedsimilarresultstothebaseanalysis(RR=1.62,95%CI1.24,2.11;I2 D 37%)
and(RR=1.73,95%CI1.40,2.13;I2 D 0),respectively.
Discontinuation of study drug due to adverse events was reported in all three trials.
In the meta-analysis of this outcome (ITT), lacosamide (all dosage arms pooled) was
associated with a signiﬁcantly higher rate of discontinuation with an RR 3.13 (95% CI
1.94, 5.06). There was no evidence of heterogeneity (I2 D 0%), see Fig. 4. Best-case and
worst-casescenarioswerenotcalculatedforthisoutcomeasnopatientdatawasmissing.
Secondary outcomes
Adverse effects outcomes
Statistically signiﬁcant changes (higher rates in the lacosamide pooled dosage arm) were
seen in the following adverse event outcomes: ataxia (RR 5.03, 95% CI 2.23, 11.37, see
Fig. 5), dizziness (RR 3.49, 95% CI 2.43, 5.01, see Fig. 6), fatigue (RR 2.04, 95% CI 1.08,
3.85, see Fig. 7) and nausea (RR 2.36, 95% CI 1.22, 4.58, see Fig. 8). No heterogeneity was
found in any of the adverse events (I2 D 0), except for nausea, which showed moderate
inconsistency,withanI2 D 34%.Fortheoutcomeofataxia,datawereincludedifoutcomes
werereportedasataxiaor“coordinationabnormal”.
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 12/26Figure4 Discontinuationduetoadverseevents(ITT). Lacosamide (all dosage arms pooled) compared to placebo.
Figure5 Ataxia. Lacosamide (all dosage arms pooled) compared to placebo.
Figure6 Dizziness. Lacosamide (all dosage arms pooled) compared to placebo.
All other meta-analyses and forest plots including: other adverse event outcomes
(headache,somnolence, seriousadverse events),seizure-free duringthetreatment period,
thesensitivityanalysesforbestandworstcasescenariosandthedose-responseanalysescan
befoundinFigs.S1–S10.
Quality of life outcomes
The quality of life outcomes were incompletely reported across all included studies. Mean
change in QOLIE-31 was reported in the Ben-Menachem trial (Ben-Menachem et al.,
2007) but no measure of variance (SD) was provided. The measurement of QOLIE-31
was limited by language availability. Since the measurement scale was only available in
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 13/26Figure7 Fatigue. Lacosamide (all dosage arms pooled) compared to placebo.
Figure8 Nausea. Lacosamide (all dosage arms pooled) compared to placebo.
Table 3 Quality of life outcomes. Mean change in QOLIE-31 as reported in the Ben-Menachem et al.
(2007) trial.
Placebo Lacosamide
200mg
Lacosamide
400mg
Lacosamide
600mg
QOLIE-31 median change in
overall score from baseline
 1.3 points NR 2.7 points NR
Clinical Global Impression of
Change (CGIC)
25% 35% 40% 38%
Notes.
An increase in score indicates an improvement in quality of life as measured by the score. QOLIE-31 D quality of life in
epilepsy inventory.
English, only participants from the United Kingdom or the United States of America were
able to contribute to this outcome. The Clinical Global Impression of Change (CGIC)
score was not reported as a continuous outcome (mean change), but as a dichotomous
outcomefrom“Verymuchimproved”or“muchimproved”frombaselinetomaintenance.
No denominators for the groups were provided. There was a numerically larger change
in seizure frequency in the lacosamide arms compared to the placebo arms. Although
Hal´ asz et al. (2009) reported that they would measure quality of life outcomes; these
were not reported in the ﬁnal publication. The quality of outcome scales as reported by
Ben-Menachemetal.(2007)areprovidedinTable3.
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 14/26Economic outcomes
No trials reported on hospital admission, length of stay, length of stay in a specialized
epilepsyunitoreconomicoutcomes.
Additional analysis
TheplannedsensitivityanalysesfortheprimaryeYcacyoutcomeand50%responderrate
wereultimatelynotundertakenduetothesmallnumberofstudiesandlackofinformation
relatingtothepre-speciﬁedsubgroups.
Post-hoc exploratory analyses were undertaken to explore a dose-eVect relationship
with eYcacy and safety for two of the primary outcomes. The diVerent dosage arms of
lacosamide vs. placebo were placed into separate subgroups to explore the dose response
of the outcomes for 50% responder-rate and discontinuation of study drug. Both analyses
showed that, as the lacosamide dose increased, so too did the trend in the 50% response
rate (P for interaction D 0.26) (Fig. S7) and the discontinuation of study drug due to
adverseevents(PforinteractionD0.03)(Fig.S8).
Asapost-hocanalysis,wealsopooledthelacosamide100mgBIDand200mgBIDarms
(200 mg or less) and compared them to the 300 mg BID arm (greater than 200 mg). These
analyses (Figs. S9 and S10) support the previous ﬁnding that higher doses of lacosamide
are associated with greater risk of drug discontinuation due to adverse events (RR 2.28,
95%CI1.46,3.58;I2 D 0%).
Risk of bias across studies
No statistical heterogeneity (I2 D 0%) was found in the analyses of the primary outcomes
and in the majority of the outcomes assessed in the meta-analysis. Funnel plot asymmetry
was not tested because only three studies were included in this meta-analysis, rendering
thistestunreliable(Sterne,Egger&Moher,2011).
Where heterogeneity did exist in the pre-speciﬁed analyses (nausea, 50% responder
rate worst-case scenario analysis), it was small to moderate with non-signiﬁcant p-values.
Potential sources of heterogeneity could be: (1) the diVering dosage arms of lacosamide
used in the trials and, (2) the diVering lengths of treatment (dose-titration was 4 weeks in
onetrialand6intheothertwotrials).
Selective reporting was evident in all three studies included in this review. Consulting
the FDA approval documents provided a more complete list of outcomes to be measured
in the trials but no details could be obtained on many outcomes, including one of the
pre-deﬁned primary outcomes - change in seizure frequency from baseline. This was the
statedprimaryoutcomeinallthreetrials,butwasnotreportedinanyofthepublications.
The quality of evidence was downgraded for risk of bias and imprecision where
appropriate (Guyatt et al., 2008). See the Summary of Findings for the statistically
signiﬁcantoutcomesfromthisreview(Table4).
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Summary of evidence
Overall, the evidence from three included trials supports that lacosamide improves the
50% responder rate compared to placebo in adults with partial-onset seizures. The
reduction in seizures demonstrated by this eYcacy outcome must be weighed against
theincreasedrateofdiscontinuationduetoadverseeventsandtheriskofincreasedataxia,
dizziness,fatigue,andnausea.
Post-hoc analysis demonstrated a possible dose-response relationship with 50%
responder rate. While post-hoc analyses should always be interpreted cautiously, the test
for interaction for discontinuation of study drug due to adverse events was statistically
signiﬁcant(p D 0:03),indicatingthatthisisanimportantareaforfutureresearch.
Incomplete outcome reporting impacted the ﬁnal results of this systematic review. As
study authors did not report the mean seizure frequency in each group, no quantitative
analysescouldbeconductedonthechangeinseizurefrequency,oneofthea prioriprimary
outcomes of this review. Quality of life outcomes were only selectively reported, and
the data available for this review were not amenable to meta-analysis. All of the authors
mentionedthatlacosamidehadafavourableeVectonQOLmeasures.
None of the included trials reported on economic outcomes. From a strict drug cost
perspective,lacosamideisfarmoreexpensivecomparedtootheravailableAEDs(TableS3).
Comparative trials with other AEDs would be helpful in determining the most cost
eVectiveroleinthetreatmentofseizures.
Theﬁndingsfromthisreviewcanbedirectlyappliedtoambulatorypatientswithpartial
epilepsy, who are refractory to their current AED therapy. Hospitalized patients were not
includedinanyofthetrialsinthisreview.
Limitations
This systematic review used a robust search strategy to consider all of the best available
publishedandunpublishedevidenceoflacosamideinpartial-onsetseizuresinadults;how-
evertherewereafewlimitationstothisreview.Thepost-hocanalysesindicatethepossible
presence of a dose-response for eYcacy and adverse eVects for lacosamide. The pooling of
all lacosamidedoses as the comparatorarm compared to placebocould underestimate the
beneﬁtofthehigherdosesand/oroverestimatetheeVectofthelowerdoseswithrespectto
eYcacy. This pooling of all dose arms of lacosamide would be expected to similarly aVect
theadverseeventsoutcomesifadose-responserelationshipexists.
All of the included studies (which formed the basis of regulatory approvals) were of a
very short duration (three months of maintenance therapy), which may have exaggerated
theeYcacyoflacosamideasadjunctiveAEDtherapy,giventhatthesetherapiesareusually
administeredformanyyears.Theseregulatoryapprovaltrialstendtohavelimitedexternal
generalizability due to exclusion of patients with co-morbidities which are common in a
largepercentageofepilepticpatients(Chungetal.,2009b;Jatuzisetal.,2005).
The search strategy was not designed to retrieve economic analyses, so relevant
economicstudiesonlacosamidecouldhavebeenmissed.
Sawh et al. (2013), PeerJ, DOI 10.7717/peerj.114 17/26Incomplete reporting of outcomes precluded meta-analysis of the mean change in
seizure frequency, one of the primary outcomes of this review. Overall, included studies
were of moderate quality, as selective outcome reporting, using non-intention-to-treat
analyses, and imprecision resulted in a downgrade in the quality of evidence of these
randomized controlled trials. In this review, the risk for reporting bias, as evidenced by
selective outcome reporting for all included trials, is judged to be the biggest threat to
validity.Sinceonlythreestudieswereincluded,publicationbiascouldnotbeexplored.
This review does not apply to the pediatric population, as the two trials including
patients less than 18 years old (Chung et al., 2010b; Hal´ asz et al., 2009) did not provide
separatedataonthepediatricparticipants.
Implications for future research
Futureresearch(bothrandomizedcontrolledtrialsandsystematicreviews/meta-analyses)
shouldconsiderthefollowing:
(1) The pediatric population remains largely unstudied and should be addressed as a
distinctsubgroupofpatientswithspecialattentiontoadverseevents.
(2) The relative eYcacy and safety of lacosamide in comparison to alternative AEDs
has not been prospectively studied and is critically important to best inform clinical
decision-making.
(3) Threecost-eVectivenessanalyses(Europeanhealthcarepayerperspective)werefound
(Simoens et al., 2010; Soini, Martikainen & Vanoli, 2009; Bolin, Berggren & Forsgren,
2010). These analyses do not have direct applicability to the Canadian health care
system. Additional cost-eVectiveness analyses using multiple perspectives (including
Provincial health system payers and society) are required in order to support eVective
decisionmakingwithinthecontextoftheCanadianHealthCaresystem.
(4) Antiepileptics (such as lacosamide), while eYcacious, are not a cure for epilepsy and
can have wide-ranging side eVects for patients. To better understand the implications
of lacosamide therapy in the life of a patient with epilepsy, quality of life assessments
and results should be reported completely. The results of the post-hoc dose-response
analyses in this review warrant further a priori exploration with respect to safety and
eYcacybothinfutureRCTsandsystematicreviews.
CONCLUSIONS
Thisreviewprovidesevidencethatlacosamideasadjunctivetherapyinadultpatientswith
partial-onsetseizuresincreasesthe50%responderrate,butwithsigniﬁcantlymoreadverse
events compared to placebo. The results are in agreement with the previously-published
pooled studies and meta-analyses (Beydoun et al., 2009; Chung et al., 2010a; Costa et al.,
2011; Ryvlin, Cucherat & Rheims, 2011) whilst providing a more accurate (ITT) summary
estimateofbeneﬁtforlacosamideandadetailedlookatriskofindividualadverseevents.
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